Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024-April 2025.
- DOI
- 10.1016/j.vaccine.2026.128964
- Published
- 2026 Aug 13
- Container
- Vaccine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2026.128964,
title = {Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024-April 2025.},
author = {Maeda H and Igarashi A and Mitsui S and Suzuki K and Kutomi T and Fujino H and Onoe T and Kimura T and Ichigi Y and Kozai H and Komazaki T and Kida S and Fujisawa A and Morimoto K},
year = {2026},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2026.128964},
url = {https://doi.org/10.1016/j.vaccine.2026.128964}
}RIS
TY - JOUR TI - Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024-April 2025. AU - Maeda H AU - Igarashi A AU - Mitsui S AU - Suzuki K AU - Kutomi T AU - Fujino H AU - Onoe T AU - Kimura T AU - Ichigi Y AU - Kozai H AU - Komazaki T AU - Kida S AU - Fujisawa A AU - Morimoto K PY - 2026 JO - Vaccine DO - 10.1016/j.vaccine.2026.128964 UR - https://doi.org/10.1016/j.vaccine.2026.128964 ER -
APA
H, M., A, I., S, M., K, S., T, K., H, F., T, O., T, K., Y, I., H, K., T, K., S, K., A, F., & K, M. (2026). Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged ≥60 years, Japan, October 2024-April 2025.. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128964
Source records
- pubmed · retrieved 2026-09-26T18:22:46.733Z